Compare EVTL & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVTL | IVVD |
|---|---|---|
| Founded | 2016 | 2020 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 607.7M | 659.8M |
| IPO Year | N/A | 2021 |
| Metric | EVTL | IVVD |
|---|---|---|
| Price | $5.36 | $2.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $13.20 | $8.75 |
| AVG Volume (30 Days) | 1.5M | ★ 3.2M |
| Earning Date | 03-13-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $50,039,000.00 |
| Revenue This Year | N/A | $107.86 |
| Revenue Next Year | N/A | $146.53 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 332.71 |
| 52 Week Low | $2.76 | $0.35 |
| 52 Week High | $7.60 | $3.07 |
| Indicator | EVTL | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 41.83 | 37.85 |
| Support Level | $5.41 | $2.15 |
| Resistance Level | $6.00 | $2.31 |
| Average True Range (ATR) | 0.42 | 0.18 |
| MACD | -0.13 | -0.06 |
| Stochastic Oscillator | 10.78 | 6.88 |
Vertical Aerospace Ltd is engaged in making air travel personal, on-demand, and carbon-free. The company is a world-wide aerospace and technology company that is pioneering electric aviation, focused on designing, manufacturing, and selling a zero operating emission eVTOL aircraft for use in the AAM market, using the technology from the aerospace, automotive, and energy industries. The VX4, Vertical's flagship aircraft, is a piloted electric vertical take-off and landing (eVTOL) vehicle capable of carrying four passengers. The Group operates as a single operating segment and one reporting segment, being the development and commercialization of eVTOL technology.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.